Fournier Pharma and Xytis Pharmaceutcials sign licensing agreement for Anatibant

14-Jun-2005

Fournier Pharma and Xytis Pharmaceuticals Ltd. announced that they have signed an agreement for the development and commercialisation of Anatibant (LF16-0687MS), a potential new medication for the treatment of traumatic brain injury, originating from Fournier Pharma's Research.

Fournier Pharma has granted Xytis an exclusive worldwide license for the development, manufacture and sale of the product containing its bradykinin B2 antagonist Anatibant for traumatic brain injury and possibly other indications. Fournier Pharma has retained full rights to manufacture the compound. The parties do not wish to disclose further details on the transaction.

Jean-Louis Junien, Chief Scientific Officer, Fournier Pharma, said: "Development in brain trauma is complex, but Anatibant is a very promising compound. Because its mechanism targets the treatment of cerebral edema, it should reduce early mortality, prevent long-term functional handicap and improve neurological outcome. I am pleased that this innovative compound from our Research Group is progressing into phase II with Xytis."

Dr. Werner Tschollar, founder and CEO of Xytis Pharmaceuticals Ltd., said: "Traumatic brain injury is an area of high unmet medical need. Anatibant belongs to the therapeutic class of bradykinin B2 inhibitors, which has demonstrated in previous clinical and non-clinical studies a potential benefit for the prevention of secondary brain damage in traumatic brain injury. We believe that Anatibant has a very good chance of becoming the first ever marketed drug improving TBI patients' clinical outcome."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances